| Literature DB >> 32238826 |
Hui Zhang1, Shou-Jiang Li1, Hai Zhang1,2, Zi-Yi Yang1, Yan-Qiong Ren1, Liang-Yong Xia1, Yong Liang3.
Abstract
The widespread applications of high-throughput sequencing technology have produced a large number of publicly available gene expression datasets. However, due to the gene expression datasets have the characteristics of small sample size, high dimensionality and high noise, the application of biostatistics and machine learning methods to analyze gene expression data is a challenging task, such as the low reproducibility of important biomarkers in different studies. Meta-analysis is an effective approach to deal with these problems, but the current methods have some limitations. In this paper, we propose the meta-analysis based on three nonconvex regularization methods, which are L1/2 regularization (meta-Half), Minimax Concave Penalty regularization (meta-MCP) and Smoothly Clipped Absolute Deviation regularization (meta-SCAD). The three nonconvex regularization methods are effective approaches for variable selection developed in recent years. Through the hierarchical decomposition of coefficients, our methods not only maintain the flexibility of variable selection and improve the efficiency of selecting important biomarkers, but also summarize and synthesize scientific evidence from multiple studies to consider the relationship between different datasets. We give the efficient algorithms and the theoretical property for our methods. Furthermore, we apply our methods to the simulation data and three publicly available lung cancer gene expression datasets, and compare the performance with state-of-the-art methods. Our methods have good performance in simulation studies, and the analysis results on the three publicly available lung cancer gene expression datasets are clinically meaningful. Our methods can also be extended to other areas where datasets are heterogeneous.Entities:
Mesh:
Year: 2020 PMID: 32238826 PMCID: PMC7113298 DOI: 10.1038/s41598-020-62473-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The sensitivity, specificity and accuracy of coefficient β of the seven methods: presented values are the mean (standard error).
| meta-Half | Sensitivity | 0.9693 (1.70 | 0.9215 (4.97 | 0.9229 (1.30 |
| Specificity | 0.9862 (2.26 | 0.9903 (6.36 | 0.9837 (1.40 | |
| Accuracy | 0.9861 (2.24 | 0.9901 (6.50 | 0.9835 (1.41 | |
| meta-MCP | Sensitivity | 0.9651 (1.90 | 0.9205 (2.70 | |
| Specificity | 0.9884 (4.18 | 0.9840 (2.02 | 0.9846 (1.15 | |
| Accuracy | 0.9883 (4.16 | 0.9838 (2.05 | 0.9840 (1.13 | |
| meta-SCAD | Sensitivity | 0.9306 (2.07 | 0.9392 (2.50 | |
| Specificity | 0.9903 (1.44 | 0.9853 (1.20 | 0.9505 (4.20 | |
| Accuracy | 0.9903 (1.42 | 0.9850 (1.44 | 0.9504 (4.10 | |
| meta-LASSO | Sensitivity | 0.9065 (8.42 | 0.9217 (6.60 | |
| Specificity | 0.9710 (2.72 | 0.9869 (3.07 | 0.9940 (1.71 | |
| Accuracy | 0.9708 (2.79 | 0.9866 (3.02 | 0.9935 (1.69 | |
| composite MCP | Sensitivity | 0.8454 (1.46 | 0.5428 (1.23 | 0.3167 (7.60 |
| Specificity | 0.9988 (6.02 | 0.9992 (4.85 | 0.9984 (7.02 | |
| Accuracy | 0.9985 (6.12 | 0.9969 (1.02 | 0.9922 (1.18 | |
| group Bridge | Sensitivity | 0.8734 (7.77 | 0.6856 (1.11 | 0.2842 (6.27 |
| Specificity | 0.9997 (2.84 | 0.9999 (1.05 | 0.9999 (3.49 | |
| Accuracy | 0.9994 (3.42 | 0.9983 (6.08 | 0.9934 (6.74 | |
| group exponential LASSO | Sensitivity | 0.8809 (8.70 | 0.7315 (1.67 | 0.4661 (2.29 |
| Specificity | 0.9984 (1.10 | 0.9981 (9.33 | 0.9976 (1.33 | |
| Accuracy | 0.9981 (1.09 | 0.9967 (8.01 | 0.9928 (1.37 |
Figure 1The sensitivity trend of coefficient β for all seven methods with the varying levels of heterogeneity.
The description of three publicly available lung cancer gene expression datasets.
| Dataset | No. of Probs | Classes (Class 0/Class 1) | No. of samples (Class 0/Class 1) | Affymetrix Platform |
|---|---|---|---|---|
| GSE10072 | 22284 | Normal/ Lung Cancer | 107 (49/58) | U133A |
| GSE19188 | 54675 | Normal/ Lung Cancer | 156 (65/91) | U133 Plus 2.0 |
| GSE19804 | 54676 | Normal/ Lung Cancer | 120 (60/60) | U133 Plus 2.0 |
Performance comparisons of different methods in three lung cancer datasets. Presented values are the average (standard error).
| Methods | Training data | Testing data | ||||
|---|---|---|---|---|---|---|
| Accuracy | Sensitivity | Specificity | Accuracy | Sensitivity | Specificity | |
| meta-Half | 0.9766 (2.69E-02) | 0.9673 (9.10E-03) | 0.9903 (1.54E-05) | 0.9449 (2.16E-02) | 0.9464 (7.93E-03) | 0.9437 (1.66E-05) |
| meta-MCP | 0.9903 (8.56E-05) | 0.9452 (1.99E-03) | 0.9439 (1.35E-04) | |||
| meta-SCAD | 0.9727 (3.13E-03) | 0.9608 (1.77E-03) | 0.9903 (2.19E-02) | 0.9464 (4.80E-03) | 0.9577 (2.50E-02) | |
| meta-LASSO | 0.9309 (1.01E-02) | 0.8722 (1.87E-02) | 0.8953 (2.11E-02) | 0.8291 (3.58E-02) | ||
| composite MCP | 0.9353 (1.45E-02) | 0.9221 (2.05E-02) | 0.9519 (1.85E-02) | 0.8656 (1.94E-02) | 0.8283 (2.23E-02) | 0.9060 (2.85E-02) |
| group Bridge | 0.6410 (1.88E-02) | 0.4039 (2.59E-02) | 0.9508 (2.23E-02) | 0.6255 (2.06E-02) | 0.3240 (3.15E-02) | 0.9317 (2.98E-02) |
| group exponential Lasso | 0.9385 (9.78E-03) | 0.9155 (1.64E-02) | 0.9655 (1.48E-02) | 0.8942 (1.85E-02) | 0.8432 (2.47E-02) | 0.9589 (2.05E-02) |
Figure 2Training and testing prediction performance of different methods on lung cancer datasets. (a) Training. (b) Testing.
Gene selections of seven methods in three lung cancer datasets.
| GSE10072 | GSE19188 | GSE19804 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| meta-Half | CXCL13 | MMP12 | COL11A1 | CXCL13 | MMP12 | COL11A1 | CXCL13 | SPINK1 | AGER |
| TOX3 | SPINK1 | FCN3 | TOX3 | SPINK1 | FCN3 | SPP1 | COL10A1 | GPM6A | |
| SPP1 | COL10A1 | SPP1 | COL10A1 | MMP12 | TOX3 | ||||
| GPM6A | AGER | GPM6A | AGER | ||||||
| meta-MCP | CXCL13 | SPP1 | COL11A1 | CXCL13 | SPP1 | COL11A1 | CXCL13 | SPP1 | |
| AGER | MMP12 | FCN3 | AGER | MMP12 | FCN3 | AGER | MMP12 | ||
| PPAP2C | COL10A1 | PPAP2C | COL10A1 | PPAP2C | COL10A1 | ||||
| GPM6A | TOX3 | GPM6A | TOX3 | GPM6A | TOX3 | ||||
| TOP2A | TMEM100 | TOP2A | TMEM100 | TOP2A | TMEM100 | ||||
| meta-SCAD | CXCL13 | MMP12 | COL11A1 | CXCL13 | MMP12 | COL11A1 | CXCL13 | MMP12 | COL11A1 |
| CYP4B1 | SPINK1 | FCN3 | CYP4B1 | SPINK1 | FCN3 | CYP4B1 | SPINK1 | FCN3 | |
| SPP1 | AGER | SPP1 | AGER | SPP1 | AGER | ||||
| meta-LASSO | PPBP | SFTPC | SPP1 | PPBP | SFTPC | SPP1 | PPBP | SFTPC | SPP1 |
| CLDN10 | AKR1B10 | SFTPD | CLDN10 | AKR1B10 | SFTPD | CLDN10 | AKR1B10 | SFTPD | |
| UPK3B | APOLD1 | XIST | UPK3B | APOLD1 | XIST | UPK3B | APOLD1 | XIST | |
| SPINK1 | COL10A1 | SPINK1 | COL10A1 | SPINK1 | COL10A1 | ||||
| HLA-DQA1 /// LOC100509457 | HLA-DQA1 /// LOC100509457 | HLA-DQA1 /// LOC100509457 | |||||||
| composite MCP | SOSTDC1 | COL11A1 | SYNE1 | SOSTDC1 | COL11A1 | ||||
| group Bridge | P2RY14 | P2RY14 | ATP1A2 | P2RY14 | |||||
| group | GDF10 | FABP4 | COL11A1 | GDF10 | FABP4 | COL11A1 | GDF10 | FABP4 | COL11A1 |
| exponential | |||||||||
| LASSO | |||||||||
Figure 3Overlap of commonly selected genes across the different methods in lung cancer datasets. (a) GSE10072 and GSE19188. (b) GSE19804.
Figure 4Network view of the genes selected from meta-Half in lung cancer datasets. The genes corresponding to the selected variables are highlighted by a thicker black outline. The rest of the nodes correspond to the genes that are frequently altered and are known to interact with the highlighted genes (based on publicly available interaction data). The nodes are gradient color-coded according to the alteration frequency based on microarray data derived from the TCGA lung cancer dataset via cBioPortal. (a) GSE10072 and GSE19188. (b) GSE19804.
Figure 5Network view of the genes selected from meta-MCP in lung cancer datasets. (a) GSE10072 and GSE19188. (b) GSE19804.
Figure 6Network view of the genes selected from meta-SCAD in lung cancer datasets. (a) GSE10072 and GSE19188. (b) GSE19804.